Your browser doesn't support javascript.
loading
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Kongtim, P; Adekola, K; Milton, D R; Ramlal, R; Jimenez, A; Chen, J; Rondon, G; Ahmed, S; Kebriaei, P; Betul, O; Hosing, C M; Popat, U; Khouri, I; Jabbour, E; Cortes, J E; Kantarjian, H M; Champlin, R E; Ciurea, S O.
Afiliação
  • Kongtim P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Adekola K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Milton DR; Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Ramlal R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Jimenez A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Chen J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Rondon G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Ahmed S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Betul O; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Hosing CM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Popat U; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Khouri I; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Jabbour E; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Cortes JE; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian HM; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Ciurea SO; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Leukemia ; 31(7): 1654-1657, 2017 07.
Article em En | MEDLINE | ID: mdl-28400618
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Leucemia Mielogênica Crônica BCR-ABL Positiva / Condicionamento Pré-Transplante / Sobrevivência de Enxerto Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Leucemia Mielogênica Crônica BCR-ABL Positiva / Condicionamento Pré-Transplante / Sobrevivência de Enxerto Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article